Passage Bio to Present at Piper Jaffray 31st Annual Healthcare Conference

PHILADELPHIA, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system diseases, today announced that management will present at the Piper Jaffray 31st Annual Healthcare Conference on Thursday, December 5^th, 2019 at 8:30 a.m. ET in New York, NY.

About Passage Bio
Passage Bio is a privately-held genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania (Penn) and its Gene Therapy Program (GTP). The GTP conducts IND-enabling preclinical work and Passage Bio conducts all clinical development, regulatory strategy and commercialization activities under the agreement. The company has a development portfolio of six product candidates, with the option to license six more, with lead programs in GM1 gangliosidosis, Fronto-Temporal dementia and Krabbe disease. Since inception, Passage Bio has raised $225 million with investments from OrbiMed, Versant Ventures, Frazier Healthcare Partners, Access Biotechnology, Lily Asia Ventures, New Leaf Venture Partners, Vivo Capital, and Boxer Capital of Tavistock Group, among others.

For further information, please contact:

Investors:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Media:
Emily Maxwell
HDMZ
312-506-5220
[email protected]

You May Also Be Interested In

• Osivax and GC Biopharma Enter Strategic Collaboration to Develop a Next-Generation Influenza Vaccine Combining OVX836 and GC FLU
• 121eCommerce Delivers Full Magento-to-Hyva Migration for IWAE, Cutting Load Times and Modernizing Checkout On Schedule
• NBPE Announces Transaction in Own Shares